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A phase 3 randomized placebo-controlled
trial of tadalafil for Duchenne muscular
dystrophy
ABSTRACT
Objective: To conduct a randomized trial to test the primary hypothesis that once-daily tadalafil,
administered orally for 48 weeks, lessens the decline in ambulatory ability in boys with Duchenne
muscular dystrophy (DMD).
Methods: Three hundred thirty-one participants with DMD 7 to 14 years of age taking glucocorti-
coids were randomized to tadalafil 0.3 mg$kg21$d21, tadalafil 0.6 mg$kg21$d21, or placebo. The
primary efficacy measure was 6-minute walk distance (6MWD) after 48 weeks. Secondary effi-
cacy measures included North Star Ambulatory Assessment and timed function tests. Perfor-
mance of Upper Limb (PUL) was a prespecified exploratory outcome.
Results: Tadalafil had no effect on the primary outcome: 48-week declines in 6MWDwere 51.06
9.3 m with placebo, 64.7 6 9.8 m with low-dose tadalafil (p 5 0.307 vs placebo), and 59.1 6
9.4 m with high-dose tadalafil (p 5 0.538 vs placebo). Tadalafil also had no effect on secondary
outcomes. In boys .10 years of age, total PUL score and shoulder subscore declined less with
low-dose tadalafil than placebo. Adverse events were consistent with the known safety profile of
tadalafil and the DMD disease state.
Conclusions: Tadalafil did not lessen the decline in ambulatory ability in boys with DMD. Further
studies should be considered to confirm the hypothesis-generating upper limb data and to deter-
mine whether ambulatory decline can be slowed by initiation of tadalafil before 7 years of age.
Clinicaltrials.gov identifier: NCT01865084.
Classification of evidence: This study provides Class I evidence that tadalafil does not slow ambu-
latory decline in 7- to 14-year-old boys with Duchenne muscular dystrophy. Neurology®
2017;89:1811–1820
GLOSSARY
AUC 5 area under the concentration-time curve; cGMP 5 cyclic guanosine monophosphate; DMD 5 Duchenne muscular
dystrophy; MMRM 5 mixed-effects model with repeated measurement; NO 5 nitric oxide; nNOSm 5 muscle-specific splice
variant of neuronal nitric oxide synthase; NSAA 5 North Star Ambulatory Assessment; PDE5 5 phosphodiesterase type 5;
PUL 5 Performance of Upper Limb; SAE 5 serious adverse event; 6MWD 5 6-minute walk distance.
Dystrophin mutations cause the most common muscular dystrophy, Duchenne muscular dys-
trophy (DMD), a devastating x-linked muscle-wasting disease.1,2 Boys are diagnosed as toddlers,
and most lose ambulation by 12 to 15 years of age. Average life expectancy isz30 years due to
respiratory failure and cardiomyopathy.1 Corticosteroids can prolong ambulation by 2 to 3
years, reduce the risk of scoliosis, and temper pulmonary and possibly cardiac decline, but they
cause well-known side effects.1 Thus, a more effective therapy is an urgent need.
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Dystrophin is both a structural sarcolemma-
stabilizing protein and a scaffolding protein that
targets partner proteins to the sarcolemma.3,4
Among these is a muscle-specific variant of neu-
ronal nitric oxide (NO) synthase (nNOSm), the
main enzymatic source of NO in skeletal
muscle.5 Sarcolemmal nNOSm increases its enzy-
matic activity and thus NO–cyclic guanosine
monophosphate (cGMP) signaling during exer-
cise6 and is implicated in muscle blood flow
regulation and mitochondrial biogenesis, micro-
tubule organization, and sarcolemmal targeting
of other dystrophin-associated proteins.7–10 The
NO generated modulates adrenergic vasocon-
striction in exercising skeletal muscle, thereby
optimizing perfusion (a protective mechanism
called functional sympatholysis).11–13 In DMD,
dystrophin deficiency disrupts sarcolemma tar-
geting of nNOSm,5 contributing to dystrophic
muscle pathology7–10,14 and causing defective
blood flow regulation.15–17 Consequently,
repeated bouts of functional muscle ischemia
could accelerate use-dependent injury of skeletal
muscle fibers already weakened by loss of
dystrophin.18
A compelling body of preclinical research in
mouse, zebrafish, and dog models of DMD
implicates the NO-cGMP pathway as a puta-
tive new drug target for DMD.6,10,19–30 Short-
term dosing of tadalafil, a phosphodiesterase
type 5 (PDE5) inhibitor that boosts defective
NO-cGMP signaling in skeletal muscle micro-
vessels, prevents exercise-induced muscle
ischemia, injury, and fatigue in mdx mice.23,24
Short-term dosing of tadalafil also ameliorates
forearm muscle ischemia during handgrip
exercise in boys with DMD15 and men with
Becker muscular dystrophy,31 a milder form of
dystrophinopathy. Whether these effects
translate to a meaningful clinical benefit is
unknown.
Accordingly, we conducted a phase 3 clini-
cal trial to test the primary hypothesis that
once-daily tadalafil, administered orally for
48 weeks, lessens the decline in ambulatory
ability in boys with DMD. In addition, we
explored the effect on upper limb function
due to its slower decline.32
METHODS Standard protocol approvals, registrations,
and patient consents. The study protocol and consent forms
were approved by the institutional review/ethics boards at each
participating medical center and conducted in accordance with
the Declaration of Helsinki and other international ethics guide-
lines. Written informed consent was obtained from parents or
guardians, and written assent was obtained from participants.
This trial is registered at ClinicalTrials.gov (NCT01865084).
Participants. The diagnostic criteria for DMD were onset of
clinical signs or symptoms before 6 years of age, markedly high
serum creatine kinase level, and deletion or duplication dystrophin
mutation or nearly absent dystrophin protein on muscle biopsy.1
Inclusion criteria were male with proven DMD, age of 7 to
14 years, 6-minute walk distance (6MWD) between 200 and
400 m, 2 baseline 6MWDs differing by ,20%, left ventricular
ejection fraction $50%, and systemic corticosteroid therapy for
$6 months with a stable regimen $3 months. Exclusion criteria
were heart failure; rhythm other than sinus or abnormal conduc-
tion on ECG; continuous mechanical ventilation; medication
other than corticosteroids affecting muscle strength; other con-
ditions affecting muscle performance; history of renal insuffi-
ciency, retinal disorder, hypotension, or uncontrolled
hypertension; or cytochrome P450 3A4 inhibitor treatment.
Study design. We conducted a phase 3 randomized, placebo-
controlled, parallel 3-arm trial of tadalafil in patients with
DMD in 63 sites in 15 countries.
Randomization and blinding. Randomization was 1:1:1
(computer-generated random sequence) to placebo, tadalafil 0.3
mg/kg (low dose), or tadalafil 0.6 mg/kg (high dose). Randomi-
zation was stratified by site and baseline 6MWD ,300 or
$300 m. Siblings were assigned to the same group. Total daily
dose was determined by baseline weight. All participants received
the same number of identical-appearing tablets. Patients, parents/
guardians, investigators, evaluators, and other study staff were
blinded to group assignment.
Procedures. Evaluation of the primary outcome and other
efficacy measures. The primary efficacy measure was the 6MWD
assessed with a 6-minute walk test modified for boys with DMD
(standardized verbal encouragement and a safety chaser).33 The
6MWD was assessed twice at baseline and once every 12 weeks
thereafter.
Secondary efficacy measures included the North Star Ambulatory
Assessment (NSAA), a 17-item evaluation of standing ability and
other timed function tests.34 The total raw NSAA score was trans-
formed to a linear 0-to-100 scale. Data are expressed as time to
perform each test, the physical therapist’s score, and velocity.
Exploratory efficacy measures included the Performance of
Upper Limb (PUL), pulmonary function, and resting heart rate.
Total PUL scale (0–72 points) is a functional assessment for
upper limb activities of daily living that includes a total of 22
individual tests of motor performance with subscores at the level
of the shoulder (high level, 0–16 points), elbow (midlevel, 0–32
points), and hand/fingers (distal level, 0–24 points). A prespeci-
fied subgroup analysis was done for boys with DMD .10 years
of age, the age at which the total PUL scale begins to decline, with
a proximal-to-distal gradient.32 Substudies aimed to explore leg
muscle fat fraction by MRI at 4 centers and functional sympa-
tholysis at 1 center.
Evaluators were trained physical therapists/physiotherapists. As-
sessments were performed in the same order (NSAA, 4-stair climb/
descend, PUL, and 6MWD) generally at the same time of day.
The Pediatric Outcomes Data Collection Instrument was the
main quality-of-life assessment.33
Drug exposures. Population pharmacokinetic modeling was
used to estimate steady-state tadalafil exposures. Blood samples
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were collected at various time intervals after dosing. Data are ex-
pressed as the mean area under the concentration-time curve (AUC).
Safety. Safety measures included adverse events, laboratory
data, vital signs, physical growth, ECGs, and echocardiograms.
Statistics. Assuming an SD of 60 m, 102 patients per group pro-
vided 90% estimated power to detect a between-group difference
of 30 m in change in 6MWD, which is clinically meaningful.33
Efficacy analyses on the full dataset were by intention to treat. A
mixed-effects model with repeated measurements (MMRM) was
used to test the primary null hypothesis of no difference between
tadalafil and placebo in mean change in 6MWD at 48 weeks.
The model included a continuous fixed effect for baseline 6MWD
and fixed categorical effects of group assignment, visit, group-by-
visit interaction, and country. Secondary and exploratory efficacy
measures also were analyzed byMMRM. Fisher exact test was applied
to categorical safety measures to flag potential treatment differences.
A multiplicity adjustment controlled for global type I error.
Tests of the primary hypothesis and those conducted under the
multiplicity adjustment are considered scientifically confirma-
tory, while all others are considered hypothesis generating.
Prespecified subgroup analyses were conducted on the primary
outcome by baseline 6MWD ,300 or $300 m and PUL scores/
subscores by baseline age#10 or.10 years. Subgroup analyses used
MMRM with addition of subgroup, subgroup-by-treatment interac-
tion, and subgroup-by-treatment-by-visit interaction. For each sub-
group analysis, a significant interaction was defined at the 0.10 level.
Primary research question. Does daily tadalafil treatment
lessen the decline in ambulatory ability in boys with DMD?
Classification of evidence. This study provides Class I
evidence that tadalafil does not slow ambulatory decline
in 7- to 14-year old boys with DMD who are taking
corticosteroids.
RESULTS The first patient enrolled in September
2013, and the last patient visit for the double-blind
trial was in December 2015. An open-label exten-
sion study was stopped in January 2016 because ta-
dalafil had no effect on the primary and secondary
efficacy endpoints of the trial. Here, we report the
major outcomes of the double-blind trial.
Patient characteristics. In total, 331 patients were ran-
domized and 316 patients completed the trial (figure 1).
One patient randomized to high-dose tadalafil was
excluded from the safety analysis because he dis-
continued before the first dose, but his data were
included in the efficacy analysis.
Baseline characteristics were similar across treat-
ment groups, with some exceptions (table 1). On
average, patients in the placebo group were younger
and had a higher baseline 6MWD compared to those
in the tadalafil groups, and a smaller proportion of
patients in the placebo group had a baseline 6MWD
,300 m. The proportion of patients unable to rise
from floor independently and unable to perform the
4-stair climbing and descending tasks was higher in
the low-dose tadalafil group compared with the pla-
cebo and high-dose tadalafil groups. A higher
Figure 1 Patient disposition
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proportion of boys in the placebo group were taking
deflazacort (table 1).
Primary efficacy measure. Tadalafil had no effect on the
primary outcome. After 48 weeks, 6MWD declined by
251.06 9.3 m with placebo vs264.76 9.8 m with
low-dose tadalafil (p 5 0.307 vs placebo) and 259.1
6 9.4 m with high-dose tadalafil (p 5 0.538 vs
placebo) (figure 2). Baseline values of 6MWD and
percent of predicted 6MWD were slightly less in the
tadalafil groups; however, both measures declined in
parallel regardless of group assignment (figure 2).
After 48 weeks, 37.9% of participants in the pla-
cebo group experienced persistent 10% worsening
in 6MWD compared with 37.3% in the low-dose ta-
dalafil group (p5 1.000) and 44.2% in the high-dose
tadalafil group (p 5 0.350); 7 (6.0%) participants in
the placebo group lost ambulation compared to 16
(15.7%) in the low-dose tadalafil group (p 5 0.027)
and 9 (8.0%) in the high-dose tadalafil group
(p 5 0.613).
As expected, 6MWD declined more steeply in pa-
tients with baseline 6MWD ,300 m. However, ta-
dalafil had no effect on either subgroup (figure e-1 at
Neurology.org).
Secondary efficacy measures. Tadalafil had no effect on
secondary outcomes. NSAA data are shown in figure
Table 1 Demographics and baseline characteristics
Placebo
(n 5 116)
Tadalafil 0.3 mg/kg
(n 5 102)
Tadalafil 0.6 mg/kg
(n 5 113)
Total
(n 5 331)
Age, mean (SD), y 9.4 (1.76) 9.9 (2.26) 9.5 (1.71) 9.6 (1.92)
Weight, mean (SD), kg 31.8 (9.97) 34.1 (11.84) 32.0 (11.16) 32.6 (10.99)
BMI, mean (SD), kg/m2 19.7 (4.45) 20.2 (4.26) 19.6 (4.79) 19.8 (4.51)
6MWD, mean (SD), m 337.5 (51.20) 323.4 (56.08) 327.0 (58.59) 329.6 (55.47)
6MWD <300 m at baseline, % 22.4 27.5 27.4 25.7
Predicted 6MWD, mean (SD), % 55.4 (9.23) 53.0 (10.08) 54.0 (10.56) 54.2 (9.98)
NSAA total score, mean (SD) 20.2 (7.04) 20.1 (7.63) 19.8 (7.16) 20.1 (7.25)
Rise from floor, mean (SD), s 8.4 (4.83) 9.6 (6.86) 10.2 (7.06) 9.4 (6.30)
Unable to rise from floor, % 22.4 30.4 25.7 26.0
10-m walk/run, mean (SD), s 6.6 (1.90) 6.8 (2.09) 6.9 (1.93) 6.8 (1.97)
Unable to walk/run 10 m, % 0 0 0 0
Stair climb, mean (SD), s 7.1 (5.48) 7.7 (11.40) 8.0 (6.98) 7.6 (8.12)
Unable to climb 4 stairs, % 0.9 6.9 0.9 2.7
Stair descend, mean (SD), s 5.8 (5.24) 5.7 (5.04) 6.4 (6.19) 6.0 (5.52)
Unable to descend 4 stairs, % 2.6 6.9 0.9 3.3
DMD mutation type, n (%)
Exon deletion 69 (59.5) 67 (65.7) 67 (59.3) 203 (61.3)
Exon duplication 20 (17.2) 14 (13.7) 20 (17.7) 54 (16.3)
Subexonic insertion/deletion 6 (5.2) 4 (3.9) 2 (1.8) 12 (3.6)
Nonsense/missense 3 (2.6) 3 (2.6) 4 (3.5) 10 (3.0)
Other/not done 18 (15.5) 12 (11.8) 19 (16.8) 49 (14.8)
Corticosteroid therapy type, n (%)
Prednisone/prednisolone 58 (50.0) 59 (57.8) 61 (54.0) 178 (53.8)
Deflazacort 58 (50.0) 43 (42.2) 51 (45.1) 152 (45.9)
Corticosteroid therapy frequency, n (%)
Daily 85 (73.3) 71 (69.6) 82 (72.6) 238 (71.9)
Every other day 20 (17.2) 16 (15.7) 17 (15.0) 53 (16.0)
2 Times every weekend 1 (0.9) 5 (4.9) 2 (1.8) 8 (2.4)
Intermittent 4 (3.4) 6 (5.9) 4 (3.5) 14 (4.2)
Other 6 (5.2) 4 (3.9) 7 (6.2) 17 (5.1)
Abbreviations: BMI 5 body mass index; DMD 5 Duchenne muscular dystrophy; NSAA 5 North Star Ambulatory
Assessment; 6MWD 5 6-minute walking distance.
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2B and figure e-2, and timed function test data are given
in tables e-1 and e-2 and figure e-3. The only statistically
positive finding was a smaller decline in velocity of the
rise from floor with low-dose tadalafil, but the difference
compared with placebo was trivial (figure e-3).
Tadalafil had no effect on the decline in parent-rated
quality of life (figure e-4). Data are not reported for ado-
lescent self-rated data because the numbers of adolescent
participants were too small (7–11 per group).
Exploratory efficacy measures. PUL. As expected, PUL
declined only in the prespecified subgroup of boys
.10 years of age (n 5 75). Their total PUL score
and shoulder subscore declined less with low-dose
tadalafil (n 5 33) than placebo (n 5 20) (figure 3).
After 48 weeks, total PUL score declined by 4% with
placebo vs 1% with low-dose tadalafil (p5 0.02) and
shoulder subscore by 14% with placebo vs 4% with
low-dose tadalafil (p 5 0.04). Total PUL score and
shoulder subscore also tended to decline less (p. 0.1)
with high-dose tadalafil (n 5 22) than placebo. The
age-by-treatment interaction p value was 0.056 and
0.060 for the total PUL score and shoulder subscore,
respectively. Elbow and hand/finger scores were
unchanged with placebo and tadalafil even in older
boys (figure e-5).
Pulmonary function. Pulmonary function tests
showed little, if any, decline, as expected for this
age group, with no treatment effect (table e-3).
Resting heart rate. Resting heart rate by ECG tended
to be slightly lower with tadalafil treatment, but this
tendency was not statistically significant. After 48
weeks, heart rate tended to decline by 1.6 bpm from
baseline with placebo compared with 3.8 bpm with
low-dose tadalafil (p 5 0.182 vs placebo) and 2.4
bpm with high-dose tadalafil (p 5 0.635 vs placebo).
Substudies. Data are not reported because too few
participants completed either the leg fat MRI sub-
study (n 5 9 per group) or the sympatholysis sub-
study (n 5 2 or 3 per group).
Compliance and drug concentration measurements.
Mean compliance in all groups exceeded 97% at
every visit. Tadalafil steady-state mean AUCs were
Figure 2 Mean change in efficacy measures
(A) Mean change from baseline to week 48 in 6MWD. (B) Mean change from baseline to week 48 in NSAA (linearized score on
scale of 0–100). (C) Mean 6MWD (meters), baseline to week 48. (D) Mean percent of predicted 6MWD, baseline to week 48.
*Primary efficacy endpoint. Analyses for each efficacy parameter included all patients with nonmissing baseline and at least
1 nonmissing postbaseline value (for 6MWD: n5113 in placebo, 101 in tadalafil 0.3mg/kg, and 111 for tadalafil 0.6 mg/kg;
for NSAA: n 5 116 in placebo, 102 in tadalafil 0.3 mg/kg, and 112 for tadalafil 0.6 mg/kg). LS 5 least squares; NSAA 5
North Star Ambulatory Assessment; 6MWD 5 6-minute walk distance.
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6550 ng $h/mL and 9380 ng $ h/mL during dosing
with 0.3 and 0.6 mg/kg, respectively. Participant-
specific data showed no association between tadala-
fil AUC values and changes in 6MWD (figure e-6).
Safety. Serious adverse events (SAEs), treatment-
emergent adverse events, or adverse events leading
to discontinuation were similar across groups (table 2).
Adverse events related to study drug were reported
in 41.4%, 50.0%, and 59.8% of patients in the
placebo, low-dose, and high-dose tadalafil groups,
respectively; the difference between high-dose ta-
dalafil and placebo was significant (p 5 0.006). The
treatment-emergent adverse events of “erection
increased” with high-dose tadalafil (15.2%, p ,
0.001) and “spontaneous penile erection” with low-
dose tadalafil (12.7%, p 5 0.012) and high-dose
tadalafil (11.6%, p 5 0.023) were reported at
a higher frequency than with placebo. Individual SAEs
(table e-4) were consistent with the type of events ex-
pected for patients with DMD receiving corticosteroid
therapy; the most frequently reported SAEs were falls,
fractures, and infections. No deaths occurred.
Changes in left ventricular ejection fraction were
small with no group differences (table e-5). There
were no differences between the tadalafil and pla-
cebo groups in safety monitoring data by laboratory
parameters, vital signs, height, body weight, or
ECG.
DISCUSSION In the largest DMD clinical trial to
date and the first to explore upper limb performance,
48 weeks of tadalafil did not lessen the decline in
6MWD or other measures of ambulatory ability in
boys with DMD7 to 14 years of age receiving standard
glucocorticoid therapy. Yet, in a prespecified subgroup
analysis of boys .10 years of age, tadalafil was associ-
ated with a lesser decline in upper limb function.
Figure 3 Mean change in total and shoulder level PUL score
(A) Total PUL score in the total population (n5 114 in placebo, 99 in tadalafil 0.3 mg/kg, and 107 in tadalafil 0.6 mg/kg). (B) Total PUL score in patients#10
years of age (n5 95 in placebo, 68 in tadalafil 0.3 mg/kg, and 85 in tadalafil 0.6 mg/kg). (C) Total PUL score in patients.10 years of age (n5 19 in placebo,
31 in tadalafil 0.3 mg/kg, and 22 in tadalafil 0.6 mg/kg). (D) Shoulder-level PUL subscore in the total population (n5 116 in placebo, 101 in tadalafil 0.3 mg/kg,
and 111 in tadalafil 0.6 mg/kg). (E) Shoulder-level PUL subscore in patients #10 years of age (n 5 96 in placebo, 69 in tadalafil 0.3 mg/kg, and 89 in tadalafil
0.6 mg/kg). (F) Shoulder-level PUL subscore in patients.10 years of age (n5 20 in placebo, 32 in tadalafil 0.3 mg/kg, and 22 in tadalafil 0.6 mg/kg). Changes in
total PUL score are from a total score range of 0 to 72; changes in shoulder-level PUL are from a total score range of 0 to 16. Higher score represents better
function. Analyses for each efficacy parameter included all patientswith nonmissing baseline and at least 1 nonmissing postbaseline value. *p,0.05. LS5 least
squares; PUL 5 Performance of Upper Limb.
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That tadalafil caused no discernible stabilization of
ambulatory ability stands in marked contrast to the
solid preclinical foundation of the trial, involving 3
different models. In the mdx mouse, multiple genetic
and pharmacologic strategies that boost NO-cGMP
signaling, including short- or long-term dosing of
PDE5 inhibitors, markedly ameliorate many features
of the dystrophic phenotype.6,10,19,20,23,24,26–30,35 In
mdx mice, even short-term dosing of either tadalafil
or sildenafil abrogates muscle ischemia, injury, and
fatigue after downhill (eccentric) treadmill exercise23
and doubles horizontal walking distance, the mouse
equivalent of 6MWD.24 Long-term sildenafil rescues
dystrophic skeletal and cardiac muscle and prolongs
survival in dystrophin-deficient zebrafish,22 and long-
term tadalafil improves skeletal muscle histopathol-
ogy and delays the onset of cardiomyopathy in the
virulent large-animal golden retriever model.21
A short-term dosing study conducted in boys with
DMD 8 to 13 years of age taking corticosteroids
informed the tadalafil doses for this clinical trial.15
Tadalafil improved blood flow regulation in
exercising forearm muscle in a dose-dependent man-
ner without affecting blood flow in resting forearm
muscle. The oral tadalafil was dosed short term at 0.5
or 1.0 mg/kg (approximating maximum adult doses
for erectile dysfunction or pulmonary hypertension,
respectively). For transition to once-daily administra-
tion in the trial, doses are 30% lower because tadalafil
has a long elimination half-life and thus accumulates
in plasma.36
Several other strengths of the trial design include
the unprecedented DMD sample size and outstand-
ing cohort retention and medication compliance with
pharmacokinetic proof that the study achieved
desired levels of 24-hour drug exposure. In our pedi-
atric DMD participants, the 2 daily tadalafil doses
produced steady-state drug concentrations that were
comparable to those achieved when healthy adults
are given the maximal allowable daily doses36,37 but
unrelated to individual differences in the primary
study outcome of 6MWD. Thus, the negative pri-
mary and secondary outcomes were not due to insuf-
ficient statistical power or drug exposure. We do not
Table 2 Adverse events
Placebo
(n 5 116), n (%)
Tadalafil 0.3 mg/kg
(n 5 102), n (%)
Tadalafil 0.6 mg/kg
(n 5 112), n (%)
Serious AEs 5 (4.3) 4 (3.9) 6 (5.4)
AE leading to discontinuation 2 (1.7) 2 (2.0) 1 (0.9)
Treatment-related AEs 48 (41.4) 51 (50.0) 67 (59.8)
Patients with ‡1 TEAEs 101 (87.1) 90 (88.2) 97 (86.6)
Headache 36 (31.0) 39 (38.2) 43 (38.4)
Fall 25 (21.6) 18 (17.6) 23 (20.5)
Nasopharyngitis 16 (13.8) 7 (6.9) 18 (16.1)
Erection increased 3 (2.6) 9 (8.8) 17 (15.2)a
Vomiting 14 (12.1) 6 (5.9) 17 (15.2)
Spontaneous penile erection 4 (3.4) 13 (12.7)a 13 (11.6)a
Upper respiratory tract infection 10 (8.6) 10 (9.8) 12 (10.7)
Diarrhea 10 (8.6) 6 (5.9) 10 (8.9)
Pain in extremity 8 (6.9) 6 (5.9) 10 (8.9)
Pyrexia 5 (4.3) 11 (10.8) 10 (8.9)
Abasia 7 (6.0) 14 (13.7) 9 (8.0)
Abdominal pain 6 (5.2) 4 (3.9) 9 (8.0)
Abdominal pain upper 7 (6.0) 5 (4.9) 8 (7.1)
Flushing 3 (2.6) 8 (7.8) 8 (7.1)
Back pain 9 (7.8) 11 (10.8) 7 (6.3)
Epistaxis 5 (4.3) 10 (9.8) 6 (5.4)
Influenza 9 (7.8) 8 (7.8) 5 (4.5)
Nausea 2 (1.7) 7 (6.9) 3 (2.7)
Abbreviations: AE 5 adverse event; TEAE 5 treatment-emergent adverse event.
Data are number of patients with $1 events.
ap , 0.05 vs placebo.
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believe the negative outcomes are explained by the
somewhat lower mean baseline values of 6MWD in
the tadalafil groups because baseline 6MWDwas a co-
variate in the primary analysis and no tadalafil effect
was seen when the analysis was stratified by baseline
6MWD .30 or 300 m.
In the placebo group, the decline in total PUL
score, mainly from a decline in shoulder function,
confirms natural history data in DMD showing pro-
gressive decline in PUL after, but not before, age 10
with a proximal-to-distal gradient.32 In older boys,
the slower decline in shoulder function and thus total
PUL score with low-dose tadalafil should be inter-
preted cautiously and considered hypothesis generat-
ing. The lack of significant treatment effect with
high-dose tadalafil may be due to this smaller sample
of the subgroup. Thus, without further study, the
treatment effect seen with low-dose tadalafil is of
uncertain clinical significance.
However, the PUL data raise 2 potential explana-
tions for the negative primary outcome of the trial.
Because DMD progresses faster in lower than in
upper extremities, the boys in this trial may not have
engaged in enough daily ambulation and fatiguing leg
exercise for the drug to prevent use-dependent leg
muscle injury. In DMD, the therapeutic target of ta-
dalafil, defective NO-cGMP signaling in skeletal
muscle microvessels, regulates muscle blood flow only
when the muscles are active.15–17 Because PDE5 levels
were found in 1 study to be lower than normal in leg
muscle biopsy tissue of 4 adult men with Becker
muscular dystrophy,38 another possibility is that the
cellular target of the drug (PDE5) was lacking in
DMD leg muscle microvessels.
While PDE5 inhibitors improve cardiac function in
preclinical models of DMD,19,21,22 a cardiacMRI study
reported that systolic function possibly declined more
rapidly in 8 adult patients with DMD cardiomyopathy
treated with sildenafil than in 7 patients treated with
placebo.39 While those results might be related to sam-
ple size or more advanced cardiomyopathy at baseline
in the sildenafil group,39 we augmented cardiac safety
monitoring of our pediatric patients with serial echo-
cardiograms, which showed no adverse effect of tada-
lafil on cardiac function. Overall, safety monitoring
revealed the expected increase in penile erections with
tadalafil without priapism.
Our study has some important limitations in
methodology. Despite the expertise and training of
the physical therapists who conducted the outcome
evaluations using state-of-the-art clinical trial meth-
odology,33 the 6-minute walk test and other current
tests used to assess ambulatory (and upper limb) abil-
ity in DMD all are invariably influenced by the boys’
volition. MRI measurement of muscle fat fraction is
a more sensitive nonvolitional index of DMD disease
progression40; however, our exploratory leg muscle
MRI substudy sample was too small to be informa-
tive. We could not document the extent to which
tadalafil improved muscle blood flow regulation dur-
ing the trial because the sympatholysis substudy sam-
ple was too small. However, our previous study
strongly suggests that these doses of tadalafil should
have improved muscle blood flow regulation at least
during arm exercise.15
On the basis of the present findings, it remains
unknown whether defective blood flow regulation
during exercise in dystrophic human skeletal muscle
is merely a reliable biomarker of defective nNOSm
signaling or remains a viable therapeutic target. Fur-
ther studies should be considered both to confirm the
hypothesis-generating upper limb data and to deter-
mine whether ambulatory decline in DMD can be
slowed by initiation of PDE5 inhibition before 7
years of age.
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